- Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
- Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
- Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
- Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
- New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
- Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
More ▼
Key statistics
On Tuesday, Talis Biomedical Corp (TLIS:NAQ) closed at 8.68, -9.58% below its 52-week high of 9.60, set on May 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.51 |
---|---|
High | 8.83 |
Low | 8.50 |
Bid | 8.60 |
Offer | 8.69 |
Previous close | 8.44 |
Average volume | 6.49k |
---|---|
Shares outstanding | 1.82m |
Free float | 1.67m |
P/E (TTM) | -- |
Market cap | 15.38m USD |
EPS (TTM) | -31.44 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 20:53 BST.
More ▼